store at low temperature | store at -80°C
Itolizumab (Anti-Human CD6 Recombinant Antibody) 是一种人源化针对 CD6 的细胞外 SRCR 远端结构域 1的重组 抗 CD6 单克隆抗体。Itolizumab 可减缓 T 细胞增殖并抑制促炎细胞因子的产生。Itolizumab 可用于研究银屑病、类风湿性关节炎 (RA)和 COVID-19 疾病等多种疾病。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 3,730 | 现货 | ||
5 mg | ¥ 7,880 | 现货 | ||
10 mg | ¥ 10,800 | 现货 | ||
25 mg | ¥ 15,900 | 现货 | ||
50 mg | ¥ 21,700 | 现货 | ||
100 mg | ¥ 29,300 | 现货 |
产品描述 | Itolizumab (Anti-Human CD6 Recombinant Antibody) is a recombinant anti-CD6 monoclonal antibody that humanizes the extracellular SRCR distal domain 1 of CD6. Itolizumab slows T cell proliferation and inhibits the production of pro-inflammatory cytokines. Itolizumab can be used to study conditions as diverse as psoriasis, rheumatoid arthritis (RA) and COVID-19 disease. |
体外活性 |
Inhibiting T cell proliferation, Itolizumab is effective at a concentration of 100 μg/mL[1]. In PBMCs, Itolizumab (0-100 μg/mL) inhibits Treg polarization and enhances the acquisition of the Th1 phenotype[1]. During overnight culture of PBMCs, Itolizumab at 40 μg/mL reduces CD26hiCD161+ CD8+ T cells[2]. In PBMCs stimulated in Th17 polarizing conditions, Itolizumab at 40 μg/mL for 3-12 days reduces the expression of IL-17 and IFN-γ[3]. |
体内活性 | In a humanized xenograft mouse model of Graft Vs Host Disease (GVHD), Itolizumab demonstrates therapeutic efficacy when administered intraperitoneally at doses of 60 μg or 300 μg daily[4]. |
别名 | EQ-001 |
分子量 | N/A |
CAS No. | 1116433-11-4 |
store at low temperature | store at -80°C
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Itolizumab 1116433-11-4 Others EQ 001 EQ-001 EQ001 Inhibitor inhibitor inhibit